CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses

Th17 responses are critical to a variety of human autoimmune diseases, and therapeutic targeting with monoclonal antibodies against IL-17 and IL-23 has shown considerable promise. Here, we report data to support selective bromodomain blockade of the transcriptional coactivators CBP (CREB binding pro...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Proc Natl Acad Sci U S A
Asıl Yazarlar: Hammitzsch, Ariane, Tallant, Cynthia, Fedorov, Oleg, O’Mahony, Alison, Brennan, Paul E., Hay, Duncan A., Martinez, Fernando O., Al-Mossawi, M. Hussein, de Wit, Jelle, Vecellio, Matteo, Wells, Christopher, Wordsworth, Paul, Müller, Susanne, Knapp, Stefan, Bowness, Paul
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: National Academy of Sciences 2015
Konular:
Biological Sciences
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4553799/
https://ncbi.nlm.nih.gov/pubmed/26261308
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1501956112
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller